血浆D-二聚体评估非霍奇金淋巴瘤疗效的价值

目的:研究非霍奇金淋巴瘤患者治疗前后血浆D-二聚体水平变化在疗效评估中的价值。方法:回顾性分析2012年1月至2014年12月苏州大学附属常州肿瘤医院收治的经病理证实的非霍奇金淋巴瘤患者50例，研究患者血浆D-二聚体水平与临床病理特征之间的相关性，评估患者治疗前后血浆D-二聚体水平变化与疗效的相关性。结果:非霍奇金淋巴瘤患者初诊时血浆D-二聚体水平中位数为0.353mg/L，高于正常范围。高龄、LDH水平升高、β2微球蛋白水平升高、临床分期晚、有B症状及国际预后指数(IPI)评分＞2分的患者D-二聚体水平明显升高(P<0.05)。治疗有效组D-二聚体水平由治疗前的0.425mg/L降低至0.105mg/L，差异有统计学意义(P<0.05)；治疗无效组D-二聚体水平由治疗前的0.263mg/L升高至0.612mg/L，差异有统计学意义(P<0.05)。结论:非霍奇金淋巴瘤患者血浆D-二聚体水平明显升高，且与临床病理特征相关，治疗前后血浆D-二聚体水平的变化可为疗效评估提供一定的依据。

Clinical significance of plasma D -dimer level in therapeutic evaluation of patients with non -Hodgkin's lymphoma

Objective:To explore the clinical significance of plasma D -dimer level before and after therapy in pa-tients with non -Hodgkin's lymphoma.Methods:Fifty patients admitted to Changzhou Tumor Hospital Affiliated to Soochou University and pathologically diagnosed with non -Hodgkin's lymphoma were retrospectively analyzed to ex-plore the relationship between patients'plasma D -dimer level and their clinical pathology.Meanwhile,the association between patients'plasma D -dimer level change after therapy and therapeutic effect were also evaluated.Results:The median plasma D -dimer level in non -Hodgkin's lymphoma patients(0.353mg/L)was higher than that in normal population(<0.300mg/L).The plasma D -dimer level had obvious correlation with age,level of LDH,level of β2 -microglobulin,clinical stage,B symptom and IPI score.The level of plasma D -dimer in positive response group was significantly decreased from 0.425mg/L to 0.105mg/L after therapy(P <0.05),whereas that in the negtive response group was significantly increased from 0.263mg/L to 0.612mg/L(P <0.05).Conclusion:The level of plasma D -dimer may provide the basis for evaluating the therapeutic effect in patients with non -Hodgkin's lymphoma.